BioMark Diagnostics Inc.
BMKDF
$0.33
-$0.02-5.90%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 12.91% | 33.98% | -1.31% | 20.00% | -155.77% |
| Total Depreciation and Amortization | 47.42% | 72.04% | 111.36% | -42.58% | -36.89% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -84.45% | -93.41% | 332.84% | -8.94% | 173.76% |
| Change in Net Operating Assets | -146.06% | -12.40% | -518.31% | 123.76% | 264.79% |
| Cash from Operations | -265.14% | 11.90% | -97.93% | 63.57% | -988.64% |
| Capital Expenditure | -- | 22.22% | 22.22% | 100.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -75,566.67% | 22.22% | 100.00% | 100.00% |
| Total Debt Issued | 0.00% | 0.00% | 0.00% | 23.52% | 0.00% |
| Total Debt Repaid | -26.72% | -21.62% | 54.20% | 70.89% | 53.50% |
| Issuance of Common Stock | -- | -- | 737.40% | -74.02% | -69.46% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -341.14% | -132.06% | 4,396.83% | -63.72% | 288.89% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 573.15% | -14,548.21% | 1,538.74% | -63.78% | -1,433.33% |